Canaccord Genuity Maintains Their Buy Rating on Amryt Pharma (AMYT)

By Austin Angelo

In a report released yesterday, Michelle Gilson from Canaccord Genuity maintained a Buy rating on Amryt Pharma (AMYTResearch Report), with a price target of $40.00. The company’s shares closed last Tuesday at $11.45.

According to TipRanks.com, Gilson is a 5-star analyst with an average return of 34.6% and a 63.2% success rate. Gilson covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Eloxx Pharmaceuticals, and Homology Medicines.

Currently, the analyst consensus on Amryt Pharma is a Moderate Buy with an average price target of $42.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.50 and a one-year low of $7.90. Currently, Amryt Pharma has an average volume of 6,482.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).